Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Front Immunol ; 11: 345, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32194563

RESUMEN

The palladacycle complex DPPE 1.2 was previously shown to inhibit Leishmania (Leishmania) amazonensis infection in vitro and in vivo. The present study aimed to evaluate the effect of DPPE 1.2 associated with a recombinant cysteine proteinase, rLdccys1, and the adjuvant Propionibacterium acnes on L. (L.) amazonensis infection in two mouse strains, BALB/c, and C57BL/6. Treatment with this association potentiated the leishmanicidal effect of DPPE 1.2 resulting in a reduction of parasite load in both strains of mice which was higher compared to that found in groups treated with either DPPE 1.2 alone or associated with P. acnes or rLdccys1. The reduction of parasite load in both mice strains was followed by immunomodulation mediated by an increase of memory CD4+ and CD8+ T lymphocytes, IFN-γ levels and reduction of active TGF-ß in treated animals. No infection relapse was observed 1 month after the end of treatment in mice which received DPPE 1.2 associated with rLdccys1 or rLdccys1 plus P. acnes in comparison to that exhibited by animals treated with DPPE 1.2 alone. Evaluation of serum levels of AST, ALT, urea, and creatinine showed no alterations among treated groups, indicating that this treatment schedule did not induce hepato or nephrotoxicity. These data indicate the potential use of this association as a therapeutic alternative for cutaneous leishmaniasis caused by L. (L) amazonensis.


Asunto(s)
Antiprotozoarios/uso terapéutico , Cisteína Endopeptidasas/uso terapéutico , Inmunoterapia/métodos , Leishmaniasis Cutánea/tratamiento farmacológico , Propionibacterium acnes , Proteínas Protozoarias/uso terapéutico , Animales , Antiprotozoarios/administración & dosificación , Antiprotozoarios/toxicidad , Terapia Combinada , Cisteína Endopeptidasas/administración & dosificación , Cisteína Endopeptidasas/inmunología , Cisteína Endopeptidasas/toxicidad , Evaluación Preclínica de Medicamentos , Femenino , Memoria Inmunológica , Interferón gamma/metabolismo , Leishmania mexicana , Leishmaniasis Cutánea/inmunología , Ganglios Linfáticos/inmunología , Activación de Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Proteínas Protozoarias/administración & dosificación , Proteínas Protozoarias/inmunología , Proteínas Protozoarias/toxicidad , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/uso terapéutico , Proteínas Recombinantes/toxicidad , Subgrupos de Linfocitos T/inmunología , Factor de Crecimiento Transformador beta/metabolismo
2.
Allergy ; 69(2): 246-53, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24180595

RESUMEN

BACKGROUND: We aimed to investigate the efficacy, safety, and T regulatory cell response of vitamin D as an adjunct to allergen-specific immunotherapy (IT). METHODS: Fifty children with asthma and receiving pharmacotherapy were randomized into three groups as: subcutaneous IT (SCIT) along with vitamin D supplementation (650 U/day; n: 17), SCIT alone (n: 15), and pharmacotherapy alone (n: 18). All patients were evaluated at baseline, 6th and 12th months for scorings of symptoms and medication, skin prick testing, total IgE, specific IgE, and Der p 1-specific IgG4. In addition, D. pteronyssinus-induced CD4(+) CD25(+) FOXP3(+) T regulatory cell percentage, intracellular Foxp3 expression, and peripheral blood mononuclear cell IL-10 and TGF-ß responses were assessed. RESULTS: In the SCIT + vitamin D and SCIT alone groups, total asthma symptom score (TASS), total symptom score (TSS), and total medication scores (TMS) were significantly lower than pharmacotherapy group at the end of 1 year. While the comparison of delta values (Δ 6th and Δ 12th month - baseline) of those scores revealed no significant differences between the two IT groups, TASS at the 6th month was lower in the SCIT + vitamin D group compared with others. There was a significant and positive trend in the levels of Der p 1-specific IgG4 in both IT groups throughout the study period. Whereas the levels of Der p 1-induced IL-10 and TGF-ß were similar between IT groups, the mean fluorescence intensity of Foxp3 was highest in the SCIT + vitamin D group compared with others at the 12th month. The rate of discontinuation of inhaled corticosteroid (ICS) was 6/17 in SCIT + vitamin D, 3/15 in SCIT, and 0/18 in the pharmacotherapy group (P = 0.02). CONCLUSION: Both SCIT groups fared better than pharmacotherapy alone at the end of 1 year. Although the clinical and immunologic outcomes were mostly similar between the two IT groups, some favorable outcomes of vitamin D warrant further investigation in more selected populations with varying doses as adjunct to IT.


Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Antígenos Dermatofagoides/administración & dosificación , Proteínas de Artrópodos/administración & dosificación , Asma/prevención & control , Cisteína Endopeptidasas/administración & dosificación , Desensibilización Inmunológica/métodos , Hipersensibilidad/prevención & control , Vitamina D/administración & dosificación , Adolescente , Animales , Asma/inmunología , Niño , Preescolar , Dermatophagoides pteronyssinus/inmunología , Femenino , Humanos , Hipersensibilidad/inmunología , Hipersensibilidad/microbiología , Masculino
3.
Br J Nutr ; 111(6): 957-67, 2014 Mar 28.
Artículo en Inglés | MEDLINE | ID: mdl-24252432

RESUMEN

The present study aimed to investigate the effect of dietary actinidin on the kinetics of gastric digestion of beef muscle proteins and on the rate of stomach emptying in growing pigs. For this purpose, 120 pigs (mean body weight 28 (sd 2·9) kg) were fed beef muscle protein-based diets containing either actinidin (fresh green kiwifruit pulp or gold kiwifruit pulp supplemented with purified actinidin) or no actinidin (fresh gold kiwifruit pulp or green kiwifruit pulp with inactivated actinidin). Additionally, fifteen pigs were fed with a protein-free diet to determine the endogenous protein flow. Pigs were euthanised at exactly 0·5, 1, 3, 5 and 7 h postprandially (n 6 per time point for each kiwifruit diet and n 3 for protein-free diet). Stomach chyme was collected for measuring gastric retention, actinidin activity, individual beef muscle protein digestion based on SDS-PAGE and the degree of hydrolysis based on the appearance of free amino groups. The stomach emptying of DM and N was faster when actinidin was present in the diet (P< 0·05): the half gastric emptying time of DM was 137 v. 172 min ( ± 7·4 min pooled standard error) for the diets with and without actinidin, respectively. The presence of dietary actinidin in the stomach chyme increased the digestion of beef muscle protein (P< 0·05) and, more specifically, those proteins with a high molecular weight (>34 kDa; P< 0·05). In conclusion, dietary actinidin fed in the form of fresh green kiwifruit increased the rate of gastric emptying and the digestion of several beef muscle proteins.


Asunto(s)
Actinidia/química , Cisteína Endopeptidasas/administración & dosificación , Digestión/efectos de los fármacos , Vaciamiento Gástrico/efectos de los fármacos , Proteínas Musculares/metabolismo , Porcinos/fisiología , Animales , Bovinos , Cisteína Endopeptidasas/análisis , Dieta/veterinaria , Proteínas en la Dieta/administración & dosificación , Suplementos Dietéticos , Electroforesis en Gel de Poliacrilamida , Frutas/química , Hidrólisis , Masculino , Carne
4.
Clin Vaccine Immunol ; 19(2): 209-18, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22190392

RESUMEN

Influenza A/H3N2 viruses have caused the most severe epidemics since 1968 despite current immunization programs with inactivated vaccines. We undertook a side-by-side preclinical evaluation of different adjuvants (Alum, AS03, and Protollin) and routes of administration (intramuscular [i.m.] and intranasal [i.n.]) for assessing their effect on the immunogenicity and cross-reactivity of inactivated split vaccines (A/H3N2/New York/55/2004). Humoral and T cell-mediated immune responses against the homologous virus and a heterologous drifted strain (A/H3N2/Wisconsin/67/2005) were measured in BALB/c mice at 2, 6, and 19 weeks postboost. The AS03- and Alum-adjuvanted i.m. vaccines induced at least an 8-fold increase over the nonadjuvanted vaccine in functional antibody titers against both the homotypic and heterotypic strains and low IgG2a and high IgG1 levels, suggesting a mixed Th1/Th2 response with a Th2 trend. The Protollin-adjuvanted i.n. vaccine induced the lowest IgG1/IgG2a ratio, which is indicative of a mixed Th1/Th2-type profile with a Th1 trend. This adjuvanted vaccine was the only vaccine to stimulate a mucosal IgA response. Whatever the timing after the boost, both hemagglutination inhibition (HAI) and microneutralization (MN) titers were higher with the AS03-adjuvanted i.m. vaccine than with the protollin-adjuvanted i.n. vaccine. Finally, the Alum-adjuvanted i.m. vaccine and the lower-dose Protollin-adjuvanted i.n. vaccine elicited significantly higher CD4(+) Th1 and Th2 responses and more gamma interferon (IFN-γ)-producing CD8(+) T cells than the nonadjuvanted vaccine. Our data indicate that the adjuvanted vaccines tested in this study can elicit stronger, more persistent, and broader immune responses against A/H3N2 strains than nonadjuvanted inactivated influenza vaccines.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Subtipo H3N2 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/inmunología , Infecciones por Orthomyxoviridae/prevención & control , Adyuvantes Inmunológicos/administración & dosificación , Administración Intranasal , Compuestos de Alumbre/administración & dosificación , Compuestos de Alumbre/farmacología , Animales , Anticuerpos Antivirales/inmunología , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Cisteína Endopeptidasas/administración & dosificación , Cisteína Endopeptidasas/inmunología , Combinación de Medicamentos , Evaluación Preclínica de Medicamentos , Pruebas de Inhibición de Hemaglutinación , Inmunidad Celular , Inmunidad Humoral , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , Vacunas contra la Influenza/administración & dosificación , Inyecciones Intramusculares , Interferón gamma/inmunología , Lipopolisacáridos/administración & dosificación , Lipopolisacáridos/inmunología , Ratones , Ratones Endogámicos BALB C , Infecciones por Orthomyxoviridae/inmunología , Células TH1/inmunología , Células Th2/inmunología , Vacunación/métodos
5.
Eur J Pharm Biopharm ; 79(3): 566-73, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21664462

RESUMEN

We have designed an oral vaccine against Clostridium difficile infection. The virulent factor Cwp84, that is a cystein protease highly immunogenic in patients with C. difficile-associated disease, was entrapped within pectin beads. Beads encapsulating Cwp84 were shown to be stable in the simulated intestinal medium and to release the cystein protease once in the simulated colonic medium. Three groups of hamsters were immunized, the first receiving pectin beads encapsulating Cwp84, the second unloaded beads and the third one free Cwp84. After three immunizations by the intragastric route, all groups received clindamycine. Post-challenge survival with a strain of C. difficile showed that 2 days after infection, all hamsters treated with unloaded beads and all hamsters treated with free Cwp84 have deceased after 7 days, whereas about 40% of hamsters administered with Cwp84-loaded beads survived 10 days after challenge, proving that oral vaccination provides partial protection. These first data obtained with an oral vaccine against C. difficile appear promising for preventing this infection.


Asunto(s)
Vacunas Bacterianas/inmunología , Clostridioides difficile/inmunología , Infecciones por Clostridium/prevención & control , Cisteína Endopeptidasas/inmunología , Portadores de Fármacos/química , Pectinas/química , Administración Oral , Animales , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Anticuerpos Antibacterianos/sangre , Vacunas Bacterianas/administración & dosificación , Química Farmacéutica , Clostridioides difficile/enzimología , Infecciones por Clostridium/inmunología , Cricetinae , Cisteína Endopeptidasas/administración & dosificación , Cisteína Endopeptidasas/química , Modelos Animales de Enfermedad , Composición de Medicamentos , Estabilidad de Medicamentos , Ensayo de Inmunoadsorción Enzimática , Femenino , Inmunoglobulina G/sangre , Peso Molecular , Análisis de Supervivencia
6.
Trends Biotechnol ; 24(10): 433-4, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16934352

RESUMEN

Celiac disease is caused by an immune response to the dietary protein gluten. The only available treatment is the strict exclusion of gluten from the diet; however, this is marred by the virtual omnipresence of this protein. The enzymatic degradation of gluten might become an alternative to the gluten-free diet, and recent work indicates that such approaches are getting close to being tested in clinical trials.


Asunto(s)
Enfermedad Celíaca/dietoterapia , Suplementos Dietéticos , Glútenes/metabolismo , Serina Endopeptidasas/farmacología , Biotransformación/fisiología , Enfermedad Celíaca/fisiopatología , Cisteína Endopeptidasas/administración & dosificación , Cisteína Endopeptidasas/biosíntesis , Cisteína Endopeptidasas/farmacocinética , Cisteína Endopeptidasas/farmacología , Humanos , Prolil Oligopeptidasas , Serina Endopeptidasas/administración & dosificación , Serina Endopeptidasas/biosíntesis , Serina Endopeptidasas/farmacocinética
7.
J Burn Care Rehabil ; 17(4): 311-22, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8844351

RESUMEN

A novel enzymatic debriding agent was evaluated on experimental full-thickness porcine contact burns. This agent consists of a highly purified, ananain-based, cysteine protease preparation formulated in a hydrophilic cream vehicle. Debridement of full-thickness burns was found to be dependent on several factors including the concentration of enzyme in the vehicle, the duration of treatment, and the hydration status of the burn wound before treatment. With an optimized debridement regimen, burns were consistently debrided of all gelatinized tissue with two 5-hour treatments. Histologic evaluation of the debrided wounds revealed an acellular deeper dermis that was debrided of necrotic cellular debris; however, the collagen matrix of the deeper dermis remained intact. This observation was consistent with a demonstrated in vitro specificity of the ananain-based protease for gelatin over collagen. A direct comparison of debridement efficacy with sutilains ointment, showed the ananain-based, debriding enzyme preparation to provide more rapid debridement of gelatinized tissue. Enzymatically debrided wounds exhibited graft take only after surgical excision of approximately 1 mm of the remaining acellular, avascular dermis. This highly purified enzyme preparation offers the potential for rapid nonsurgical debridement of gelatinized burn tissue, but required additional surgical debridement for graft take in this porcine model.


Asunto(s)
Quemaduras/tratamiento farmacológico , Cisteína Endopeptidasas/uso terapéutico , Trasplante de Piel/patología , Animales , Quemaduras/terapia , Cisteína Endopeptidasas/administración & dosificación , Desbridamiento/métodos , Modelos Animales de Enfermedad , Frutas/enzimología , Supervivencia de Injerto , Trasplante de Piel/métodos , Porcinos , Factores de Tiempo , Cicatrización de Heridas/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA